244 related articles for article (PubMed ID: 38480932)
1. Basal-epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer.
Inayatullah M; Mahesh A; Turnbull AK; Dixon JM; Natrajan R; Tiwari VK
EMBO Mol Med; 2024 Apr; 16(4):823-853. PubMed ID: 38480932
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells.
Zeng D; Liang YK; Xiao YS; Wei XL; Lin HY; Wu Y; Bai JW; Chen M; Zhang GJ
Int J Cancer; 2020 Jul; 147(2):490-504. PubMed ID: 32020593
[TBL] [Abstract][Full Text] [Related]
3. Decoding gene regulatory circuitry underlying TNBC chemoresistance reveals biomarkers for therapy response and therapeutic targets.
Lusby R; Zhang Z; Mahesh A; Tiwari VK
NPJ Precis Oncol; 2024 Mar; 8(1):64. PubMed ID: 38472332
[TBL] [Abstract][Full Text] [Related]
4. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
5. Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.
Lee S; Hu Y; Loo SK; Tan Y; Bhargava R; Lewis MT; Wang XS
Proc Natl Acad Sci U S A; 2020 May; 117(18):9912-9921. PubMed ID: 32321829
[TBL] [Abstract][Full Text] [Related]
6. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer.
Lai YW; Hsu WJ; Lee WY; Chen CH; Tsai YH; Dai JZ; Yang CC; Lin CW
Cells; 2021 Jul; 10(8):. PubMed ID: 34440660
[TBL] [Abstract][Full Text] [Related]
8. Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer.
Assidicky R; Tokat UM; Tarman IO; Saatci O; Ersan PG; Raza U; Ogul H; Riazalhosseini Y; Can T; Sahin O
Breast Cancer Res Treat; 2022 Jun; 193(2):331-348. PubMed ID: 35338412
[TBL] [Abstract][Full Text] [Related]
9. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition.
Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C
Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034
[TBL] [Abstract][Full Text] [Related]
10. RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer.
Koh SB; Ross K; Isakoff SJ; Melkonjan N; He L; Matissek KJ; Schultz A; Mayer EL; Traina TA; Carey LA; Rugo HS; Liu MC; Stearns V; Langenbucher A; Saladi SV; Ramaswamy S; Lawrence MS; Ellisen LW
Clin Cancer Res; 2021 Sep; 27(17):4883-4897. PubMed ID: 34168046
[TBL] [Abstract][Full Text] [Related]
11. Periostin blockade overcomes chemoresistance via restricting the expansion of mesenchymal tumor subpopulations in breast cancer.
Nakazawa Y; Taniyama Y; Sanada F; Morishita R; Nakamori S; Morimoto K; Yeung KT; Yang J
Sci Rep; 2018 Mar; 8(1):4013. PubMed ID: 29507310
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition.
Garcia E; Luna I; Persad KL; Agopsowicz K; Jay DA; West FG; Hitt MM; Persad S
Sci Rep; 2021 Jun; 11(1):11757. PubMed ID: 34083676
[TBL] [Abstract][Full Text] [Related]
13. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
[TBL] [Abstract][Full Text] [Related]
14. Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy Response.
Kim J; Yu D; Kwon Y; Lee KS; Sim SH; Kong SY; Lee ES; Park IH; Park C
Mol Cancer Res; 2020 Feb; 18(2):253-263. PubMed ID: 31704731
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
Hill DP; Harper A; Malcolm J; McAndrews MS; Mockus SM; Patterson SE; Reynolds T; Baker EJ; Bult CJ; Chesler EJ; Blake JA
BMC Cancer; 2019 Nov; 19(1):1039. PubMed ID: 31684899
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
17. A prognostic gene signature for metastasis-free survival of triple negative breast cancer patients.
Lee U; Frankenberger C; Yun J; Bevilacqua E; Caldas C; Chin SF; Rueda OM; Reinitz J; Rosner MR
PLoS One; 2013; 8(12):e82125. PubMed ID: 24349199
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
19. LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis.
Du C; Wang Y; Zhang Y; Zhang J; Zhang L; Li J
Cell Transplant; 2020; 29():963689720929983. PubMed ID: 32686982
[TBL] [Abstract][Full Text] [Related]
20. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
